These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 32781041)
1. Microenvironment-Mediated Resistance to Anti-Androgen Therapy. Orme JJ; Huang H Cancer Cell; 2020 Aug; 38(2):155-157. PubMed ID: 32781041 [TBL] [Abstract][Full Text] [Related]
2. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Bastos DA; Dzik C; Rathkopf D; Scher HI Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626 [TBL] [Abstract][Full Text] [Related]
3. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer]. Hu YH; Guo JC; Zhang M Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189 [TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Zhang Z; Karthaus WR; Lee YS; Gao VR; Wu C; Russo JW; Liu M; Mota JM; Abida W; Linton E; Lee E; Barnes SD; Chen HA; Mao N; Wongvipat J; Choi D; Chen X; Zhao H; Manova-Todorova K; de Stanchina E; Taplin ME; Balk SP; Rathkopf DE; Gopalan A; Carver BS; Mu P; Jiang X; Watson PA; Sawyers CL Cancer Cell; 2020 Aug; 38(2):279-296.e9. PubMed ID: 32679108 [TBL] [Abstract][Full Text] [Related]
5. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription. Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975 [TBL] [Abstract][Full Text] [Related]
7. [Mechanisms for castration-resistance of prostate carcinoma]. Chen F; Zhao X Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1217-1221. PubMed ID: 29093256 [TBL] [Abstract][Full Text] [Related]
8. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer. Linder A; Larsson K; Welén K; Damber JE Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815 [TBL] [Abstract][Full Text] [Related]
9. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer]. Chen ZY; Dong Q; Liu LR; Wei Q Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207 [TBL] [Abstract][Full Text] [Related]
10. [Androgen biosynthesis in castration-resistant prostate cancer: Advances in studies]. Chen B; Cao DH; Guo JB; Liu LR; Wei Q Zhonghua Nan Ke Xue; 2019 Mar; 25(3):265-271. PubMed ID: 32216246 [TBL] [Abstract][Full Text] [Related]
11. Targeting androgen-independent pathways: new chances for patients with prostate cancer? Cattrini C; Zanardi E; Vallome G; Cavo A; Cerbone L; Di Meglio A; Fabbroni C; Latocca MM; Rizzo F; Messina C; Rubagotti A; Barboro P; Boccardo F Crit Rev Oncol Hematol; 2017 Oct; 118():42-53. PubMed ID: 28917268 [TBL] [Abstract][Full Text] [Related]
12. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Coutinho I; Day TK; Tilley WD; Selth LA Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360 [TBL] [Abstract][Full Text] [Related]
13. AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer. Salvi S; Conteduca V; Lolli C; Testoni S; Casadio V; Zaccheroni A; Rossi L; Burgio SL; Menna C; Schepisi G; De Giorgi U Curr Cancer Drug Targets; 2018; 18(9):869-876. PubMed ID: 29173173 [TBL] [Abstract][Full Text] [Related]
14. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864 [TBL] [Abstract][Full Text] [Related]
15. Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go? Cheng HH; Higano CS Oncology (Williston Park); 2014 Aug; 28(8):700-1. PubMed ID: 25140627 [No Abstract] [Full Text] [Related]
16. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence. Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834 [TBL] [Abstract][Full Text] [Related]
17. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
18. Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression. Dejima T; Imada K; Takeuchi A; Shiota M; Leong J; Tombe T; Tam K; Fazli L; Naito S; Gleave ME; Ong CJ Prostate; 2017 Feb; 77(3):309-320. PubMed ID: 27775154 [TBL] [Abstract][Full Text] [Related]
19. Leading causes of castration-resistant prostate cancer. Lu M; Lu H; Kong Q Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203 [TBL] [Abstract][Full Text] [Related]
20. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer. Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]